TY - JOUR
T1 - Combined docking and machine learning identifies key molecular determinants of ligand pharmacological activity on β2 adrenoceptor
AU - Jiménez‐rosés, Mireia
AU - Morgan, Bradley Angus
AU - Jimenez Sigstad, Maria
AU - Tran, Thuy Duong Zoe
AU - Srivastava, Rohini
AU - Bunsuz, Asuman
AU - Borrega‐román, Leire
AU - Hompluem, Pattarin
AU - Cullum, Sean A.
AU - Harwood, Clare R.
AU - Koers, Eline J.
AU - Sykes, David A.
AU - Styles, Iain B.
AU - Veprintsev, Dmitry B.
PY - 2022/10
Y1 - 2022/10
N2 - G protein-coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A central question of GPCR drug discovery is to understand what determines the agonism or antagonism of ligands that bind them. Ligands exert their action via the interactions in the ligand binding pocket. We hypothesized that there is a common set of receptor interactions made by ligands of diverse structures that mediate their action and that among a large dataset of different ligands, the functionally important interactions will be over-represented. We computationally docked ~2700 known ?2AR ligands to multiple ?2AR structures, generating ca 75 000 docking poses and predicted all atomic interactions between the receptor and the ligand. We used machine learning (ML) techniques to identify specific interactions that correlate with the agonist or antagonist activity of these ligands. We demonstrate with the application of ML methods that it is possible to identify the key interactions associated with agonism or antagonism of ligands. The most representative interactions for agonist ligands involve K972.68×67, F194ECL2, S2035.42×43, S2045.43×44, S2075.46×641, H2966.58×58, and K3057.32?31. Meanwhile, the antagonist ligands made interactions with W2866.48×48 and Y3167.43×42, both residues considered to be important in GPCR activation. The interpretation of ML analysis in human understandable form allowed us to construct an exquisitely detailed structure-activity relationship that identifies small changes to the ligands that invert their pharmacological activity and thus helps to guide the drug discovery process. This approach can be readily applied to any drug target.
AB - G protein-coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A central question of GPCR drug discovery is to understand what determines the agonism or antagonism of ligands that bind them. Ligands exert their action via the interactions in the ligand binding pocket. We hypothesized that there is a common set of receptor interactions made by ligands of diverse structures that mediate their action and that among a large dataset of different ligands, the functionally important interactions will be over-represented. We computationally docked ~2700 known ?2AR ligands to multiple ?2AR structures, generating ca 75 000 docking poses and predicted all atomic interactions between the receptor and the ligand. We used machine learning (ML) techniques to identify specific interactions that correlate with the agonist or antagonist activity of these ligands. We demonstrate with the application of ML methods that it is possible to identify the key interactions associated with agonism or antagonism of ligands. The most representative interactions for agonist ligands involve K972.68×67, F194ECL2, S2035.42×43, S2045.43×44, S2075.46×641, H2966.58×58, and K3057.32?31. Meanwhile, the antagonist ligands made interactions with W2866.48×48 and Y3167.43×42, both residues considered to be important in GPCR activation. The interpretation of ML analysis in human understandable form allowed us to construct an exquisitely detailed structure-activity relationship that identifies small changes to the ligands that invert their pharmacological activity and thus helps to guide the drug discovery process. This approach can be readily applied to any drug target.
KW - GPCRs
KW - adrenoceptor
KW - docking
KW - drug discovery
KW - machine learning
KW - structure-activity relationship
UR - http://www.scopus.com/inward/record.url?scp=85137135084&partnerID=8YFLogxK
U2 - 10.1002/prp2.994
DO - 10.1002/prp2.994
M3 - Article
SN - 2052-1707
VL - 10
JO - Pharmacology Research and Perspectives
JF - Pharmacology Research and Perspectives
IS - 5
M1 - e00994
ER -